Description
The IDKmonitor® vedolizumab drug level ELISA measures quantitatively free vedolizumab in EDTA plasma and serum.
Tumor necrosis factor alpha (TNFα) belongs to the proinflammatory cytokines, which promote and sustain inflammatory reactions. It is produced by macrophages and T-cells and plays a central role in both acute and chronic inflammations. As a result, chronic inflammatory diseases like Crohn’s disease, ulcerative colitis, rheumatoid arthritis, or psoriasis are increasingly being treated with antibodies against TNFa, which target directly the underlying inflammatory processes.
In combination with the detection of ADA against vedolizumab, the IDKmonitor® vedolizumab drug level ELISA is an opportunity for the treating physician to monitor and
optimize the therapy early on.
